Immune to Cancer: The CRI Blog
-
CRI to Co-Host Inaugural International Cancer Immunotherapy Conference
The 4-day “go-to” meeting for scientists, clinicians, regulators, drug developers, and patient advocates begins this week.
-
CRI’s James Allison to Receive Prestigious Lasker Award
The Lasker Foundation announced today that James P. Allison, PhD, director of CRI’s Scientific Advisory Council, is…
-
The Coveted Four Stars
For the third consecutive year, Cancer Research Institute earns top rating from Charity Navigator.
-
New Study Suggests a Common Heart Medication Could Help Cancer Patients Live Longer
A new study published yesterday in the journal Cancer suggests that a common medication known as…
-
Jimmy Carter to Receive Immunotherapy for Melanoma
The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.
-
What Patients Need to Know About Lung Cancer Immunotherapy
Join us on August 21 as Julie Brahmer, MD, discusses the latest research and current treatments for…
-
CRI Awards $29.3 Million to Fund Immunotherapies for All Kinds of Cancer
CRI committed new funds to accelerate research and clinical development.
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.